Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia

Launched by CAIRO UNIVERSITY · Jun 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat a common type of hair loss called androgenic alopecia, which often affects men. The researchers want to see if using a special technique called iontophoresis—where a mild electrical current helps deliver a medicine called minoxidil directly into the scalp—can improve hair growth more effectively than usual treatments.

Men between the ages of 18 and 65 who have been diagnosed with androgenic alopecia by their doctor and are medically and mentally stable may be able to join the study. Participants should not have any scalp infections, allergies to minoxidil or the treatment method, or other skin conditions that could interfere with the study. People currently using other hair loss treatments or with certain medical issues, such as severe mental health problems or immune system concerns, will not be eligible. If you take part, you can expect to receive the minoxidil treatment through iontophoresis and be monitored to see how well it works and if there are any side effects. This study is not yet recruiting participants but aims to find better options for treating hair loss in men.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Twenty-five adult aged 18-65 with diagnosed androgenic alopecia.
• • They diagnosed as Androgenic alopeacia by their physicians and referred for physical therapy management.
• • Medically and psychologically stable patients.
• Exclusion Criteria:
• • History of hypersensitivity to minoxidil solution or Intophoresis.
• • Scalp infection
• • Concurrent hair loss treatments.
• • Patients who suffer from hypertrophic and/or keloidal scars and a skin condition in the area of Androgenic alopecia that would interfere with study procedures.
• • plaque psoriasis, tattoo, birthmark, facial hair.
• • Patients with medical red flags as severe psychiatric disorder or cognitive deficits.
• • Medically unstable and uncooperative patients.
• • Immunocompromised status.
• • History of skin cancer.
• • Recurrent herpes viral infection.
• • Pregnancy or breastfeeding status.